HomeCompareNS vs PFE

NS vs PFE: Dividend Comparison 2026

NS yields 7.29% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $24.7K in total portfolio value· pulled ahead in Year 9
10 years
NS
NS
● Live price
7.29%
Share price
$21.96
Annual div
$1.60
5Y div CAGR
-11.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.3K
Annual income
$287.71
Full NS calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — NS vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNSPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NS + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NS pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NS
Annual income on $10K today (after 15% tax)
$619.31/yr
After 10yr DRIP, annual income (after tax)
$244.55/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $22,884.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NS + PFE for your $10,000?

NS: 50%PFE: 50%
100% PFE50/50100% NS
Portfolio after 10yr
$38.7K
Annual income
$13,749.12/yr
Blended yield
35.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NS
Analyst Ratings
6
Buy
13
Hold
3
Sell
Consensus: Hold
Price Target
$20.25
-7.8% upside vs current
Range: $19.50 — $21.00
Altman Z
1.0
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NS buys
8
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Chip Roy🏢 House$NS▼ Sell$1,001 - $15,0002024-04-10
Bill Hagerty🏛 Senate$NS▼ Sell$50,001 - $100,0002021-12-29
Bill Hagerty🏛 Senate$NS▼ Sell$50,001 - $100,0002021-12-29
Mark Dr Green🏢 House$NS▼ Sell$500,001 - $1,000,0002021-12-21
Mark Dr Green🏢 House$NS▲ Buy$100,001 - $250,0002021-10-06
Mark Dr Green🏢 House$NS▲ Buy$100,001 - $250,0002021-09-27
Mark Dr Green🏢 House$NS▲ Buy$50,001 - $100,0002021-09-14
Mark Dr Green🏢 House$NS▲ Buy$100,001 - $250,0002021-09-01
Mark Dr Green🏢 House$NS▼ Sell$250,001 - $500,0002021-08-19
Mark Dr Green🏢 House$NS▲ Buy$100,001 - $250,0002021-07-09
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNSPFE
Forward yield7.29%6.20%
Annual dividend / share$1.60$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-11.4%13.2%
Portfolio after 10y$26.3K$51.1K
Annual income after 10y$287.71$27,210.54
Total dividends collected$4.6K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$20.25$27.50

Year-by-year: NS vs PFE ($10,000, DRIP)

YearNS PortfolioNS Income/yrPFE PortfolioPFE Income/yrGap
1$11,346$645.54$9,161$701.38+$2.2KNS
2$12,746$606.45$8,610$859.79+$4.1KNS
3$14,203$564.16$8,366$1,081.25+$5.8KNS
4$15,717$520.52$8,483$1,405.66+$7.2KNS
5$17,294$476.98$9,084$1,907.24+$8.2KNS
6$18,940$434.59$10,418$2,732.78+$8.5KNS
7$20,660$394.09$13,007$4,193.56+$7.7KNS
8$22,462$355.95$18,010$7,005.87+$4.5KNS
9← crossover$24,354$320.45$28,216$12,979.89$3.9KPFE
10$26,347$287.71$51,081$27,210.54$24.7KPFE

NS vs PFE: Complete Analysis 2026

NSStock

NuStar Energy L.P. engages in the terminalling, storage, and marketing of petroleum products in the United States and internationally. The company also engages in the transportation of petroleum products and anhydrous ammonia. It operates through three segments: Pipeline, Storage, and Fuels Marketing. The Pipeline segment transports refined products, crude oil, and anhydrous ammonia. The Storage segment owns terminal and storage facilities, which offer storage, handling, and other services for petroleum products, crude oil, specialty chemicals, renewable fuels, and other liquids; and pilotage, tug assistance, line handling, launch, emergency response, and other ship services. The Fuels Marketing segment is involved in bunkering operations in the Gulf Coast; blending operations; and purchase of petroleum products for resale. As of December 31, 2021, it had 3,205 miles of refined product pipelines and 2,230 miles of crude oil pipelines in Texas, Oklahoma, Kansas, Colorado, and New Mexico; a 2,050-mile refined product pipeline originating in southern Kansas and terminating at Jamestown, North Dakota; a 450-mile refined product pipeline originating at Marathon Petroleum Corporation's Mandan, North Dakota refinery and terminating in Minneapolis, Minnesota; a 2,000-mile anhydrous ammonia pipeline; and 29 terminal and storage facilities, which offer approximately 44.2 million barrels of storage capacity. The company was incorporated in 1999 and is headquartered in San Antonio, Texas.

Full NS Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NS vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NS vs SCHDNS vs JEPINS vs ONS vs KONS vs MAINNS vs JNJNS vs MRKNS vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.